Depomed — Proxy Contest (August 2015)
34 slides from Depomed's proxy contest presentation, Aug 7, 2015
Slide 1: Transformation Complete: A Specialty Pharmaceutical Leader Focused in Pain and Neurology
Transformation Complete: A Specialty Pharmaceutical Leader Focused in Pain and Neurology August 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s acquisition of the NUCYNTA® franchise in the United States, Depomed’s p
Slide 3: Important Additional Information
Important Additional Information Depomed intends to file a revocation statement and revocation card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with a proposed solicitation by Horizon Pharma, plc to be able to call a special meeting of Depomed shareholders (the “Horizo
Slide 4: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
4 August 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity Track Record of Accelerated Growth Organic growth - success increasing product sales, script
Slide 5: Depomed's Track Record of Successful Deals Builds Value
Reworked Santarus deal and tripled net revenue 47% revenue growth Q2 2015 over Q2 2014 Acquired Dec 2013; relaunched Q1 2014; 35% increase in demand Q2 2015 over Q2 2014 Q3 2011 Q4 2011 Q4 2013 TYPE 2 DIABETES DEAL Non-strategic milestones & royalties sold for $240 million Q4 2013 Relaunch Q4 2013 f
Slide 6: Depomed's Acquire, Integrate, Grow Business Model
Depomed’s “Acquire, Integrate, Grow” Business Model Driving An Accelerated Growth Cycle 6 August 2015 ACQUIRE Pain and neurology products with lengthy exclusivity and peak sales ahead INTEGRATE Speed and efficiency from playbook based on past success with same team GROW Repositioning and marketing s
Slide 7: Business Model Driving Triple Digit Growth in Sales and Significant Profitability
Depomed’s Execution of Business Model Driving Triple Digit Growth in Sales and Significant Profitability 7 $500K $27.1M $58.1M $114M $320M-340M August 2015 2015 Total Product Sales Guidance (Includes NUCYNTA starting April 2, 2015) Adjusted EBITDA (Midpoint of adjusted EBITDA Guidance) $102.5M At Mi
Slide 8: Business Model Driving Sales Growth, Rx Growth, Market Share
Depomed Business Model Driving Sales Growth, Rx Growth, Market Share August 2015 Note: Average weekly prescriptions per Symphony Health Solutions for the 12-weeks prior to Depomed’s acquisition versus the most recent 12-week period Product Sales Growth (Y/Y) Prescription Growth (Y/Y) Market Share Gr
Slide 9: Depomed's Clear Track Record of Value Creation
Depomed’s Clear Track Record of Value Creation 9 August 2015 Data as of 7/31/2015 Depomed is in a Period of Significant Growth and We Believe is Well-Positioned for Future Success 217% 383% 471% 1001% 1-Year 2-Year 3-Year 5-Year Total Shareholder Return to Date (1)
Slide 10: Depomed 2Q 2015 - Continued Strong Performance
Depomed 2Q 2015 - Continued Strong Performance With Revenue Up 234% Over Prior Year 10 August 2015 Record Quarterly Results 2015 Guidance Updated* Additional Highlights Net product sales of $94.3M (234% over Q2 2014) Added $55M of cash in second quarter Product sales raised to $320-$340M Non-GAAP ad
Slide 11: Depomed Expected to be a Top 5 Branded Pain Company by 2016
11 11 August 2015 Acute Pain Breakthrough Cancer Pain Chronic Pain Neuropathic Pain Migraine ü ü ü ü ü ü ü ü ü ü ü ü ü ü Source: Depomed Marketing, company websites Depomed Expected to be a Top 5 Branded Pain Company by 2016 ü We Believe Depomed is Building the Most Complete Pain Portfolio in the In
Slide 12: NUCYNTA Leading The Latest Chapter of Depomed's Growth Story
NUCYNTA Leading The Latest Chapter of Depomed’s Growth Story – Blockbuster Potential Adds significant revenue and earnings to an already strong business Only new chemical entity in CII space approved by FDA in last 30 years Competes in multi-billion dollar pain market Exclusivity expected for a deca
Slide 13: NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales
Depomed’s NUCYNTA Growth Strategy – Targeting to Surpass $1 Billion in Sales 13 August 2015 Proper Dosing Pricing and Access Positioning Promotion Significantly increased promotion and marketing efforts Revamped product positioning and messaging Maximize brand through pricing and access strategies E
Slide 14: Promotion: Significantly Increased to Drive Prescriptions and Market Share
Promotion: Significantly Increased to Drive Prescriptions and Market Share 14 August 2015 Increased Sales Force 1 Optimized Medical Education Identifying Appropriate Target Prescribers Promotion strategy consists of: 3-fold increase to 275 reps Highly experienced in pain and neurology Resumed full m
Slide 15: Positioning: Only FDA Approved Product Addressing Both Nociceptive and Neuropathic Pain
Positioning: Only FDA Approved Product that Addresses Both Nociceptive and Neuropathic Pain 15 August 2015 Chronic pain affects 1/3 of the US population More than 100 million adults with chronic pain 31 million with chronic lower back pain (CLBP) Potential significant impact from even modest uptick
Slide 16: Pricing and Access: Maximize Brand Through Pricing and Access Strategies
Pricing and Access: Maximize Brand Through Pricing and Access Strategies 16 August 2015 94% of commercial lives have access to NUCYNTA and NUCYNTA ER United Healthcare Commercial moved NUCYNTA ER in front of Oxycontin on formulary as of July 1, 2015 Oxycontin removed from Tier 2 and now requires a t
Slide 17: Proper Dosing: Education on Titration is Key
Proper Dosing: Education on Titration is Key Average dose in low back pain trials was ~400mg/day after titration 17 August 2015 4 200 mg Proper Dose May Improve Physician and Patient Experience as well as Increase Average Selling Price Expert Opin. Pharmacother. (2010) 11(11):1787-1804 250 mg ~400 m
Slide 18: NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More
NUCYNTA Patent Protection Expected to Provide Market Exclusivity for a Decade or More 18 August 2015 NUCYNTA >$500MM by 2020 and $1 Billion Before Patent Expiry February 2023: Expiry of patents covering tapentadol (composition of matter plus pediatric extension) December 2025: Expiry of polymorph pa
Slide 19: Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA
19 August 2015 Depomed’s Highly Differentiated Growing Portfolio of Assets in Addition to NUCYNTA Product Differentiation 2Q Annualized Revenues Growth Over 1Q 2015 Intellectual Property 1x daily with less dizziness and somnolence $84M 21% April 2015 ANDA settlement provides exclusivity to 2024 Only
Slide 20: Depomed Sales Force Effectively Targets Key Specialties
Depomed Sales Force Effectively Targets Key Specialties Core Sales Force N=275 Cancer Pain Specialists n=24 Pain Focused Neurology Focused 20 August 2015
Slide 21: Ability to Efficiently Execute and Deliver Growth - Gralise
21 August 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Gralise Reacquired marketing rights March 2011 and received $40M payment Launched in October 2011 >$84 million run rate as of Q2 2015 Tier 2 coverage at the three largest pharmacy benefit managers, CVS/Caremark, ESI, Catama
Slide 22: Ability to Efficiently Execute and Deliver Growth - CAMBIA
22 August 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - CAMBIA Acquired in December 2013 for $48.7M Relaunched in December 2013 $27 million run rate as of Q2 2015 Only single agent in its therapeutic class approved in the U.S. for treatment of acute migraine attacks in adults Ex
Slide 23: Ability to Efficiently Execute and Deliver Growth - Lazanda
23 August 2015 Depomed’s Ability to Efficiently Execute and Deliver Growth - Lazanda Acquired in July 2013 for $4M Relaunched in August 2013 $15.4 million run rate as of Q2 2015 Market share has doubled in last 12 months and 4x since relaunch Effective January 1st, only branded rapid acting fentanyl
Slide 24: Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth
Lengthy Exclusivity Periods Mean Products Contributing to Revenue Growth for a Long Time 24 August 2015 Securing Market Exclusivity for Depomed Products Well Into Next Decade Product Expected Exclusivity 2025+ Acquired April 2015; composition of matter patent to 2022/2023; polymorph and method of tr
Slide 25: Acquire, Integrate, and Grow Strategy Will Continue to Create Value
25 August 2015 We Expect Depomed’s Acquire, Integrate, and Grow Strategy will Continue to Create Value Maintain pain and neurology focus, leveraging management’s expertise Products with current annual revenue between $20-$200MM+ Targeting products with lengthy exclusivity and future peak sales Rapid
Slide 26: Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade
Depomed’s Collaborations and Intellectual Property Provide Revenue Upside Over the Next Decade 26 IP Litigation Potential future cash flow from IP litigation against Purdue Pharma and Endo PTAB has confirmed the patentability of each of the 25 claims subject to Purdue IPRs; Endo decision expected by
Slide 27: Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth
27 August 2015 Depomed – A Force in Pain and Neurology, in a Period of Accelerated Growth Strong Product Portfolio Marketing six branded, differentiated products in pain and neurology with lengthy exclusivity Track Record of Accelerated Growth Organic growth - success increasing product sales, scrip
Slide 28: Depomed Timeline of Events Related to Hostile Proposal
Depomed Timeline of Events Related to Hostile Proposal 28 August 2015 MAY 27 Depomed receives unsolicited all stock acquisition proposal from Horizon Pharma plc with an indicated value of $29.25/share "Horizon's purported revised, unsolicited proposal does not reflect the value inherent in Depomed's
Slide 29: Percentage Ownership Offered Well Below Contribution Based on Research Median Estimates
Percentage Ownership Offered Well Below Contribution Based on Research Median Estimates 29 August 2015 Based on PF Equity Contribution (1) (2) (3) (4) (5) Notes Initial Proposal based on Depomed offer price per share of $29.25 and Horizon price per share of $31.90 (5/26/15) and net debt of $840MM an
Slide 30: Depomed's Directors are Industry Experienced
Depomed’s Directors are Industry Experienced Peter D. Staple (chair) CEO, Corium International, Inc. Vicente Anido, Jr. CEO, Aerie Pharmaceuticals, Inc. Karen A. Dawes President, Knowledgeable Decisions Louis J. Lavigne, Jr. Former CFO, Genentech, Inc. Samuel R. Saks, MD Co-Founder, Co-CEO Jazz Phar
Slide 31: Depomed has Retained Respected and Experienced Advisors
Depomed has Retained Respected and Experienced Advisors in Connection with Evaluation of Hostile Proposal Financial Advisors: Morgan Stanley & Co. LLC Leerink Partners LLC Each firm has performed substantial and customary financial analysis and separately advised Board that hostile proposal does not
Slide 32: Board Communication and Participation
Board Communication and Participation - Frequent and Open Board meetings or Board update calls at least once per week since first Horizon proposal Meetings include participation by financial advisors and counsel Additional updates from CEO to Board Chairman and other Board members Horizon board memb
Slide 33: Board Action Intended to Provide Time to Consider Hostile Proposal
Board Action Intended to Provide Depomed Board and Shareholders Time to Consider Hostile Proposal Limited duration Shareholder Rights Plan Plan expires at next annual shareholder meeting Intended to ensure all shareholders receive fair and equal treatment in any proposed takeover Bylaw amendments es
Slide 34: Thank You
pve ans < Depomed Thank You www.depomed.com